Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
TEVA PHARMA Dec-13 |
DISHMAN PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 3,125 | - | |
Low | Rs | 129 | 2,715 | - | |
Sales per share (Unadj.) | Rs | 197.8 | 1,793.5 | - | |
Earnings per share (Unadj.) | Rs | 21.2 | 112.0 | - | |
Cash flow per share (Unadj.) | Rs | 34.7 | 257.0 | - | |
Dividends per share (Unadj.) | Rs | 2.00 | 98.08 | - | |
Dividend yield (eoy) | % | 0.8 | 3.4 | 23.7% | |
Book value per share (Unadj.) | Rs | 179.9 | 1,992.3 | - | |
Shares outstanding (eoy) | m | 80.69 | 848.00 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 1.3 | 1.6 | 78.1% | |
Avg P/E ratio | x | 11.9 | 26.1 | 45.5% | |
P/CF ratio (eoy) | x | 7.2 | 11.4 | 63.8% | |
Price / Book Value ratio | x | 1.4 | 1.5 | 95.4% | |
Dividend payout | % | 9.4 | 87.5 | 10.8% | |
Avg Mkt Cap | Rs m | 20,306 | 2,476,101 | 0.8% | |
No. of employees | `000 | 0.8 | 44.9 | 1.8% | |
Total wages/salary | Rs m | 5,355 | 0 | - | |
Avg. sales/employee | Rs Th | 19,252.7 | 33,839.3 | 56.9% | |
Avg. wages/employee | Rs Th | 6,459.5 | 0 | - | |
Avg. net profit/employee | Rs Th | 2,064.1 | 2,113.9 | 97.6% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 1,520,909 | 1.0% | |
Other income | Rs m | 265 | 0 | - | |
Total revenues | Rs m | 16,226 | 1,520,909 | 1.1% | |
Gross profit | Rs m | 4,103 | 416,502 | 1.0% | |
Depreciation | Rs m | 1,091 | 122,937 | 0.9% | |
Interest | Rs m | 944 | 29,873 | 3.2% | |
Profit before tax | Rs m | 2,334 | 263,692 | 0.9% | |
Minority Interest | Rs m | 0 | 1,198 | 0.0% | |
Prior Period Items | Rs m | 1 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -173,099 | 0.0% | |
Tax | Rs m | 624 | -3,219 | -19.4% | |
Profit after tax | Rs m | 1,711 | 95,010 | 1.8% | |
Gross profit margin | % | 25.7 | 27.4 | 93.9% | |
Effective tax rate | % | 26.7 | -1.2 | -2,188.8% | |
Net profit margin | % | 10.7 | 6.2 | 171.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 1,027,216 | 1.1% | |
Current liabilities | Rs m | 9,517 | 895,820 | 1.1% | |
Net working cap to sales | % | 9.4 | 8.6 | 108.8% | |
Current ratio | x | 1.2 | 1.1 | 101.0% | |
Inventory Days | Days | 110 | 91 | 121.7% | |
Debtors Days | Days | 35 | 96 | 36.3% | |
Net fixed assets | Rs m | 16,304 | 496,762 | 3.3% | |
Share capital | Rs m | 161 | 3,744 | 4.3% | |
Net worth | Rs m | 14,516 | 1,689,442 | 0.9% | |
Long term debt | Rs m | 4,189 | 777,675 | 0.5% | |
Total assets | Rs m | 29,805 | 3,475,765 | 0.9% | |
Interest coverage | x | 3.5 | 9.8 | 35.3% | |
Debt to equity ratio | x | 0.3 | 0.5 | 62.7% | |
Sales to assets ratio | x | 0.5 | 0.4 | 122.4% | |
Return on assets | % | 8.9 | 3.6 | 248.0% | |
Return on equity | % | 11.8 | 5.6 | 209.6% | |
Return on capital | % | 17.5 | 4.9 | 355.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | 242,354 | 1.1% | |
From Investments | Rs m | -1,529 | -85,876 | 1.8% | |
From Financial Activity | Rs m | -941 | -290,720 | 0.3% | |
Net Cashflow | Rs m | 316 | -134,242 | -0.2% |
Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare DISHMAN PHARMA With: ORCHID PHARMA J.B.CHEMICALS ELDER PHARMA PIRAMAL ENTERPRISES SHASUN PHARMA
Indian share markets witnessed volatile trading activity throughout the day today and ended lower.
Ajit Dayal on how India's vaccine strategy will impact the markets.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
There is no stopping this 11-bagger stock from significant upside.
In this video I tell you the three Nifty ETFs I think are the best.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
More